Adjuvant Immunization of HLA-A2–Positive Melanoma Patients With a Modified gp100 Peptide Induces Peptide-Specific CD8+ T-Cell Responses Purpose: Successful therapeutic interventions to prevent disease ...

Osteosarcoma is a type of aggressive bone cancer that most commonly affects children and young adults between the ages of 10 and 20, during times of rapid bone growth. Although rare, it has a ...

Background Osteosarcoma is the most prevalent primary malignant bone tumor in children and adolescents. The current standard treatment involves a combination of chemotherapy and radical surgical ...

Human bone marrow under the microscope. UC Davis researchers have developed engineered bone marrow, which can be used to study treatments for osteosarcoma, one of the deadliest cancers in humans and ...

GSK’227, a B7-H3-targeted ADC, received FDA Breakthrough Therapy Designation for relapsed or refractory osteosarcoma after two prior therapies. Phase 2 ARTEMIS-002 study showed antitumor activity and ...

Scientists have demonstrated a new potential treatment for bone cancer. A bioactive glass laced with a toxic metal was able to kill up to 99% of the cancer without harming healthy cells, and could ...

Lucknow: King George's Medical University introduced a minimally invasive treatment, chemoembolization, for aggressive bone cancers, a disease that af.